{"data":{"id":114,"lang":"en","title":"Princeton Scientists Discover Vitamin A Derivative Helps Tumors Evade Immune System, Develop New Drug","summary":"Princeton researchers discover how vitamin A metabolite helps cancer evade immunity, develop promising new drug compound KyA33.","category":"science","category_label":"Science","published_at":"2026-01-24T01:36:09Z","updated_at":"2026-01-24T01:36:09Z","url":"https://techtools.cz/tools/news/article/114-princeton-scientists-discover-vitamin-a-derivative-helps-tumors-evade-immune","api_url":"https://techtools.cz/news-api/v1/articles/114?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/114.md?lang=en","image_url":"https://scx1.b-cdn.net/csz/news/800a/2026/understanding-how-vita.jpg","word_count":149,"reading_time_minutes":1,"sources":[{"url":"https://www.sciencedaily.com/releases/2026/01/260115022808.htm","domain":"sciencedaily.com"},{"url":"https://medicalxpress.com/news/2026-01-immune-sabotage-vitamin-byproduct-compromises.html","domain":"medicalxpress.com"},{"url":"https://www.ludwigcancerresearch.org/news-releases/a-nuclear-target-to-revive-anti-tumor-immunity/","domain":"ludwigcancerresearch.org"}],"translation":null,"content":"Researchers at Princeton's Ludwig Institute for Cancer Research have uncovered how retinoic acid, a metabolite of vitamin A, secretly undermines the body's anti-cancer defenses. The findings resolve a decades-old scientific paradox and point to a promising new treatment approach.\n\nThe team found that cancer cells overproduce retinoic acid not to benefit themselves, but to sabotage nearby immune cells. The compound reprograms dendritic cells—the immune system's alarm system—to tolerate tumors rather than attack them. This explains why high vitamin A intake correlates with increased cancer risk despite the nutrient's apparent anti-cancer properties in lab studies.\n\nTo counter this effect, the researchers developed KyA33, an experimental drug that blocks retinoic acid production. In animal studies, the inhibitor dramatically improved cancer vaccine effectiveness and slowed tumor growth when used alone. The team has launched biotech company Kayothera to bring ALDH1A inhibitors to clinical trials for cancer, diabetes, and cardiovascular disease."}}